For clinical implications and treatment strategies, immunohistochemistry (IHC) markers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), combined with clinicopathological variables, including tumor size, tumor grade, and nodal involvement, have been routinely utilized [3,4]. The gene discussed is PGR; the disease is neoplasm.